DOCSLIB.ORG

HIGHLIGHTS Winter 2015 for DONORS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HIGHLIGHTS Winter 2015 for DONORS HIGHLIGHTS Winter 2015 FOR DONORS The Leukemia & Lymphoma Society (LLS) exists to find cures and ensure access to treatments for all blood cancer patients. Because there are no means of preventing or screening for most blood cancers, we focus on finding cures. LLS values your generosity because progress happens when smart money and smart research meet. Harnessing A Natural Process to Kill Cancer o make room for new cells, the body tells billions of Tunwanted cells each day to die in a natural biological BH3-only proteins process known as apoptosis. If blood cells fail to die when signal cell damage they should, they can develop into leukemia, lymphoma or myeloma. A team of researchers led by Jerry Adams, PhD, Pro-survival Bcl-2 proteins at the Walter and Eliza Hall Institute of Medical Research keep Bax and Bak in check in Melbourne, Australia has received extensive funding from LLS over a dozen years to investigate how impaired Bax and Bak apoptosis contributes to blood cancers and becomes a switch on apoptosis machinery major barrier to therapy. The key regulators of cell death in lymphoma are interacting proteins of the B-cell lymphoma 2 family (BCL-2). Within that family, BH3-only proteins initiate apoptosis by transmitting signals of cellular damage and Adams’ team member, Andrew Roberts, MB, MS, PhD, inactivating the pro-survival function of other proteins. conducted a Phase 1 trial of ABT-199 as a single agent for Tumors often use pro-survival proteins to resist death. To treatment-resistant chronic lymphocytic leukemia (CLL) overwhelm those proteins and switch on the apoptosis patients. It showed marked falls in tumors in the blood and machinery, the Adams team developed BH3 mimetics, lymph nodes and reduced infiltration to the bone marrow small molecules that are capable of mimicking the BH3- in 90 percent of the patients. This substantial activity only proteins. against CLL is highly encouraging and ABT-199 is being With earlier LLS funding, the Adams team collaborated tested in Phase 1, 2 and 3 trials as a monotherapy and in with Genentech and Abbott (now known as AbbVie) to test combinations with rituximab and bendamustine. Data from a first-generation compound that targeted three pro-survival a Phase 2 trial in relapsed CLL patients are due in coming proteins in the BCL-2 family. It showed promising clinical months and could be submitted to the FDA for review. results but caused a severe decrease of platelets in the blood, To explore the full potential of the apoptotic machinery which limited dosing. The team continued the collaboration to kill tumor cells, LLS is also funding other researchers, to help develop a more specific and potent mimetic known including Anthony Letai, MD, PhD, at Dana Farber as ABT-199 that spares the platelets. Cancer Institute, studying non-Hodgkin lymphomas. www.LLS.org Right Patient, Right New AML Therapy Therapy in HCL to Watch For airy cell leukemia (HCL), a slow-growing blood IDH 1 and 2 (isocitrate dehydrogenase) are cancer that mostly affects middle-aged adults, enzymes that are mutated in many blood cancers. H IDH proteins normally break down nutrients and gets its name from the short, thin projections that generate energy; but when mutated, they prevent look like hair on its cells. HCL starts with a mutation cells from maturing to become specialized blood in the DNA of a single stem cell and multiplies cell types. In acute myeloid leukemia (AML), 15-20 uncontrollably in the bone marrow, liver and spleen. percent of patients have IDH mutations. Recent More than 90 percent of patients treated with clinical trials for two oral IDH inhibitors, AG-221 cladribine (Leustatin®) achieve complete remission and and AG-120, produced a 50-60 percent response rate in refractory AML patients. LLS funded Daniel many remain disease free for years or decades. But in Pollyea, MD, at University of Colorado in this trial about 40 percent of patients, the leukemia returns and and has other active grants at University of Toronto becomes less responsive to chemotherapy. Further, the and Memorial Sloan-Kettering Cancer Center that chemotherapy also kills normal cells in the bone marrow are also studying this target. Unlike most therapies and immune system and severe infections can follow. that seek to destroy cancer cells, this approach More specific and less toxic treatments are needed. actually transforms them into normal cells. Using next-generation sequencing technologies on more than 20,000 human genes, LLS-funded Immature researcher Enrico Tiacci, MD, in Perugia, Italy looked cell AG-120 for the activating mutation in HCL. In his study of AG-221 500 HCL patients, Dr. Tiacci found one mutation Normal X in a gene known as B-RAF in nearly all of them. This IDH 1 or 2 gene normally plays a pivotal role in the regulation of cell proliferation and survival. The mutated version was not present in other B-cell blood cancers but is AML Normal cell Tumor cell frequently found in melanoma. An oral B-RAF inhibitor, vemurafenib, which has already been found to be safe and effective in melanoma patients, offers potential for long-term control of HCL. With LLS funding, Dr. Tiacci conducted a phase 2 Long-term Investment Pays Off trial for HCL patients who do not respond or have severe side effects from standard chemotherapy. Of 26 Stephan Grupp, MD, PhD, at Children’s Hospital patients, 25 showed an overall response—nine with of Philadelphia is part of the Carl June Specialized Center of Research team to which LLS has complete remissions and 16 with partial remissions. Six committed nearly $21 million. He recently reported of those with complete remissions and five of those with long-term follow up data from an immunotherapy partial remissions had normal blood counts a year after trial with 39 children and young adults with relapsed, treatment. acute lymphoblastic leukemia (ALL). Relapsed ALL patients currently have no good treatment options. Independently, LLS-funded researcher Jae Park, MD, After the experimental therapy in which patients’ at Memorial Sloan-Kettering in New York was doing own immune T cells were genetically engineered complementary research in a Phase 2 trial of relapsed or and reintroduced to the body to kill cancer cells, refractory HCL patients treated with vemurafenib. Of 36 of 39 children achieved a complete response. 17 patients evaluated, six achieved complete remission After six months, 70 percent of those in the study and the remainder achieved partial remission. remained cancer free and 75 percent survived. Only five children received subsequent treatment. While longer-term follow up is needed, vemurafenib A Phase 2, multi-site trial will continue to study the shows promise for relapsed or refractory HCL patients. long-term efficacy of the treatment and evaluate its Subsequent studies will be needed to prove if inhibiting potential as a replacement for stem cell transplant B-RAF might be the best initial therapy. for children with relapsed, treatment-resistant ALL. Good Outcomes Require Good Diagnoses ancer complexity and diversity is a recognized ...even with today’s Creality and precisely targeted medicines are the best “ promise for patients. As more therapies are developed to advanced technology, target specific abnormalities and selectively kill cancer patients are misdiagnosed cells, accurate diagnoses, including the exact classification of lymphoma subtypes, can dramatically affect treatment with surprising frequency. selection and patient outcomes. Patients need to have ” biopsies and medical information collected, analyzed and sector experts to improve diagnostics, including the exact interpreted by an expert in hematological malignances classification of lymphoma subtypes. Initially, the two-year with the detailed diagnosis communicated to the treating project will define the magnitude and scope of lymphoma physician in a timely manner and actionable format. misdiagnoses, especially those that impact treatment Yet even with today’s advanced technology, patients selection in community treatment centers versus academic are misdiagnosed with surprising frequency. In common medical centers. Subsequent steps include the following: B-cell lymphomas, inaccurate diagnoses occur about 5 • Develop and validate diagnostic tools that utilize percent of the time and escalating to 40 percent for less widely used core biopsies and/or fine needle common lymphomas. As a result, too many patients will aspirates to diagnose recognized lymphoma receive inappropriate treatments. subtypes and select optimal treatments; Why do misdiagnoses occur? • Develop and validate a protocol(s) for automatic • Pathologists receive incomplete medical records. and timely second diagnostic opinions; • Sample collection is insufficient or inappropriate. • Evaluate new diagnostic techniques and sequential • Pathologists without specific hematopathology testing to achieve accurate diagnoses that are both experience misinterpret the data. clinically and cost effective. To address the obstacles to receiving accurate diagnoses, The goal of this partnership is to reduce costs, achieve LLS will begin a new partnership with public and private better outcomes, and save lives. Testing a New Approach for High Risk Myeloma Patients Over the past several years researchers have been This MIL therapy could be especially useful to the 20 achieving good results treating cancers with genetically percent of myeloma patients who are considered high risk and engineered cells. Known as adoptive T cell therapy, this don’t achieve long-term remissions with current therapies. method takes T cells from patients, grows them in the lab Dr. Borrello began a randomized Phase 2 clinical and returns them to the patients to destroy the cancer. trial in late 2013 to examine this therapy. It is currently Sources for the T cells often include blood or cells within enrolling high risk myeloma participants who are either a solid tumor (an approach used in treating patients newly diagnosed or in a first relapse. The first trial site with skin cancer).
Load more

Recommended publications
  • Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and P38
    Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and p38 Mitogen-activated Protein Kinase: Regulators of Distinct Cell Death and Survival Pathways in Granulocytes By Andreas Villunger,* Lorraine A. O’Reilly,* Nils Holler,‡ Jerry Adams,* and Andreas Strasser* From *The Walter and Eliza Hall Institute, Melbourne, Victoria 3050, Australia; and the ‡Institute of Biochemistry, University of Lausanne, Epalinges CH-1066, Switzerland Abstract The short life span of granulocytes, which limits many inflammatory responses, is thought to be influenced by the Bcl-2 protein family, death receptors such as CD95 (Fas/APO-1), stress-acti- vated protein kinases such as p38 mitogen-activated protein kinase (MAPK), and proinflamma- tory cytokines like granulocyte colony-stimulating factor (G-CSF). To clarify the roles of these various regulators in granulocyte survival, we have investigated the spontaneous apoptosis of granulocytes in culture and that induced by Fas ligand or chemotherapeutic drugs, using cells from normal, CD95-deficient lpr, or vav-bcl-2 transgenic mice. CD95-induced apoptosis, which required receptor aggregation by recombinant Fas ligand or the membrane-bound ligand, was unaffected by G-CSF treatment or Bcl-2 overexpression. Conversely, spontaneous and drug-induced apoptosis occurred normally in lpr granulocytes but were suppressed by G-CSF treatment or Bcl-2 overexpression. Although activation of p38 MAPK has been implicated in granulocyte death, their apoptosis actually was markedly accelerated by specific inhibitors of this kinase. These results suggest that G-CSF promotes granulocyte survival largely through the Bcl-2–controlled pathway, whereas CD95 regulates a distinct pathway to apoptosis that is not required for either their spontaneous or drug-induced death.
    [Show full text]
  • To Professor Suzanne Cory AC
    Citation for the Award of the Doctor of Laws (Honoris Causa) to Professor Suzanne Cory AC When Suzanne Cory graduated from the Science Faculty at the University of Melbourne molecular biology was in its infancy. In her enthusiasm for this new science she pursued a PhD in Cambridge at the Medical Research Council’s famed Laboratory of Molecular Biology. Immersed in a culture of discovery, her pioneering PhD studies determined the sequence of a transfer RNA, utilising new technology developed by Fred Sanger, one of the three Nobel Laureates in the institute. After three years’ post‐doctoral work at the University of Geneva, Suzanne Cory returned to Australia with her husband, Jerry Adams, to the Walter and Eliza Hall Institute of Medical Research where they helped to introduce gene‐cloning technology to Australia. Since then, her long association with the Institute, including thirteen years as Director, and with the University of Melbourne, has been instrumental in building the international reputation of both institutions and the strength of the Parkville biomedical research network. Suzanne Cory has made major contributions to advancing the science of immunology, cancer and genetics, in a lifelong dynamic research partnership with Adams. Her work is published widely and cited frequently. The positions held by the many PhD candidates and Post‐Doctoral Fellows she has supervised demonstrate her intergenerational influence in developing scientific leaders for the future. The list of accolades and awards Suzanne Cory has received in recognition of her contributions to science is long and distinguished. She was elected a Fellow of the Australian Academy of Science in 1986 and since has been elected to numerous sister organisations across the globe.
    [Show full text]
  • Huzzah to the Double Helix! It's International DNA Day | Lifehacker
    Huzzah To The Double Helix! It’s International DNA Day | L... http://www.lifehacker.com.au/2013/04/huzzah-to-the-double-h... Business Insider Gizmodo Kotaku Lifehacker PopSugar BellaSugar FabSugar ShopStyle Log In Register Life Work IT Pro RECENTLY ON KOTAKU RECENTLY ON KOTAKU Robin Has A Point In These Hilarious Conference Or Not, We’ll Cherish Superhero Texts These E3 Nintendo Memes Forever HOME Huzzah To The Double Helix! It’s International DNA Day CHRIS JAGER YESTERDAY 9:30 AM Share 5858 Discuss 22 Today is International DNA Day, which this year commemorates 60 years since the scientific paper A Structure for Deoxyribose Nucleic Acid was first published. Here’s what some of Australia’s leading scientists SUBSCRIBE have to say about the importance of the discovery… CONTACT DNA picture from Shutterstock Sixty years ago to the day, James Watson and Francis Crick published a revolutionary paper on the Like Lifehacker Australia 5,616 Followers structure of Deoxyribonucleic acid; the molecular key to all living things otherwise known as DNA. A Follow Lifehacker Australia 11,734 Followers century after Gregor Mendel first began messing about with peas, the final piece of the genetic puzzle had been slotted into place. Subscribe to all stories 15,269 Followers To mark this historic occasion, several Australian scientists have released statements in which they Australian stories 1,859 Followers basically wax lyrical about the wonders of DNA — what better way to start your morning? (And if you’re wondering what the Lifehacker angle is, the answer is quite simple: when someone smarter than you has something to say, it’s usually worth listening!) REGULARS LIFE Professor Suzanne Cory, President of the Australian Academy of Science: Sell Your Stuff And Get Some Extra Cash This Weekend The discovery of the structure of DNA by James Watson and Francis Crick was an epic moment in the history of science.
    [Show full text]
  • A Null C-Myc Mutation Causes Lethality Before 10.5 Days of Gestation in Homozygotes and Reduced Fertility in Heterozygous Female Mice
    Downloaded from genesdev.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice Ann C. Davis, 1 Marie Wims, 1 Gerald D. Spotts, 2 Stephen R. Hann, 2 and Allan Bradley 1 tlnstitute for Molecular Genetics, Baylor College of Medicine, Houston, Texas 77030 USA; ~Department of Cell Biology, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232-2175 USA To directly assess c-myc function in cellular proliferation, differentiation, and embryogenesis, we have used homologous recombination in embryonic stem cells to generate both heterozygous and homozygous c-myc mutant ES cell lines. The mutation is a null allele at the protein level. Mouse chimeras from seven heterozygous cell lines transmitted the mutant allele to their offspring. The analysis of embryos from two clones has shown that the mutation is lethal in homozygotes between 9.5 and 10.5 days of gestation. The embryos are generally smaller and retarded in development compared with their littermates. Pathologic abnormalities include the heart, pericardium, neural tube, and delay or failure in turning of the embryo. Heterozygous females have reduced fertility owing to embryonic resorption before 9.5 days of gestation in 14% of implanted embryos, c-Myc protein is necessary for embryonic survival beyond 10.5 days of gestation; however, it appears to be dispensable for cell division both in ES cell lines and in the the embryo before that time. [Key Words: c-myc; gene targeting; null mutation~ embryonic lethal] Received November 25, 1992; revised version accepted January 25, 1993.
    [Show full text]
  • 2010-2011 Annual Report
    Annual Report 2010-2011 Mastery of disease through discovery | www.wehi.edu.au Contents 1 About the institute 3 Director’s and Chairman’s report 5 Discovery 8 Cancer and Haematology 10 Stem Cells and Cancer 12 Molecular Genetics of Cancer 14 Chemical Biology 16 Molecular Medicine 18 Structural Biology 20 Bioinformatics 22 Infection and Immunity 24 Immunology The Walter and Eliza Hall Institute 26 Autoimmunity and Transplantation of Medical Research 28 Cell Signalling and Cell Death 1G Royal Parade 30 Inflammation Parkville Victoria 3052 Australia Telephone: (+61 3) 9345 2555 32 Molecular Immunology Facsimile: (+61 3) 9347 0852 34 Publications WEHI Biotechnology Centre 36 Awards 4 Research Avenue 37 Translation La Trobe R&D Park Bundoora Victoria 3086 Australia Translating our research 38 Telephone: (+61 3) 9345 2200 40 Developing our research Facsimile: (+61 3) 9345 2211 42 Patents www.wehi.edu.au www.facebook.com/WEHIresearch 43 Education www.twitter.com/WEHI_research 46 2010-11 graduates ABN 12 004 251 423 47 Seminars Acknowledgements 48 Institute awards Produced by the institute’s Community Relations department 49 Engagement Managing editor: Penny Fannin Editor: Liz Williams 51 Strategic partners Writers: Liz Williams, Vanessa Solomon and Julie Tester 52 Scientific and medical community Design and production: Simon Taplin Photography: Czesia Markiewicz and Cameron Wells 54 Public engagement 57 Engagement with schools Cover image 58 Donor and bequestor engagement Art in Science finalist 2010 Vessel webs 59 Sustainability Dr Leigh Coultas, Cancer and Haematology division 60 The Board This image shows the delicate intricacy in the developing eye of a transient population of web-like blood vessels.
    [Show full text]
  • Expression of the Other in T Cells Bim and Bcl-2 Mutually Affect
    Bim and Bcl-2 Mutually Affect the Expression of the Other in T Cells Trine N. Jorgensen, Amy McKee, Michael Wang, Ella Kushnir, Janice White, Yosef Refaeli, John W. Kappler and This information is current as Philippa Marrack of September 25, 2021. J Immunol 2007; 179:3417-3424; ; doi: 10.4049/jimmunol.179.6.3417 http://www.jimmunol.org/content/179/6/3417 Downloaded from References This article cites 54 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/179/6/3417.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Bim and Bcl-2 Mutually Affect the Expression of the Other in T Cells1 Trine N. Jorgensen,2* Amy McKee,2*ʈ Michael Wang,2† Ella Kushnir,*ʈ Janice White,*ʈ Yosef Refaeli,** John W.
    [Show full text]
  • Unmasking the Mysteries of MYC Rajeev M
    Unmasking the Mysteries of MYC Rajeev M. Nepal and Alberto Martin J Immunol 2019; 202:2517-2518; ; This information is current as doi: 10.4049/jimmunol.1900186 of October 1, 2021. http://www.jimmunol.org/content/202/9/2517 References This article cites 25 articles, 9 of which you can access for free at: Downloaded from http://www.jimmunol.org/content/202/9/2517.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on October 1, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Unmasking the Mysteries of MYC Rajeev M. Nepal* and Alberto Martin† n the early 1980s, when the oncogenic potential of MYC showing that mitogenic stimulation of cells induced the expres- was established, the scientific community was somewhat sion of MYC in a cell cycle–dependent manner (7) and that I perplexed (1). Contrary to other oncogenes known at MYC played a key role in DNA replication (8, 9).
    [Show full text]
  • Suzanne Cory’S Passion in Every Sense
    NEWS Biomedical research has been Suzanne Cory’s passion in every sense. She has worked to decode the genetic mysteries of the immune system and cancer, has rallied her country to invest in its scientific future, and is married to a fellow scientist from her post-doctoral years. Nature Medicine talked to the Director of the Walter and Eliza Hall Institute in Melbourne to find out why her love affair with science hasn’t waned in intensity over four decades. Suzanne Cory Reinvigorated from trekking in one of New stamp on Cory’s life: “It was an environ- vival in tumorigenesis. Together with Zealand’s most challenging mountain ment steeped in scientific passion and rigor Adams and a PhD student, David Vaux, ranges during a rare break from work, Cory —four Nobel laureates and ambitious post- Cory discovered that BCL-2, the oncogene was brimming with enthusiasm. docs from all around the world, hungry for activated by chromosome translocation in Uppermost is excitement about her in- success. It was there that I realized that human follicular lymphoma, had a very volvement in a consortium bidding for the there are no half measures in science — the different mode of action than all previ- Federal Government’s Biotechnology commitment has to be all or nothing.” ously characterized oncogenes. Rather Center of Excellence—the winner will be And it was there that she met fellow scien- than stimulating cell proliferation, BCL-2 announced later this year. Cory and her tist Jerry Adams. They married and em- promotes cell survival. “Nobody then colleagues have the bold vision of estab- barked on a research career together, dreamed that simply stopping a cell from lishing a Therapeutics Development which began with post-docs in Geneva.
    [Show full text]
  • Perforin-Mediated Suppression of B-Cell Lymphoma
    Perforin-mediated suppression of B-cell lymphoma Paul Bolithoa,b, Shayna E. A. Streeta, Jennifer A. Westwooda, Winfried Edelmannc, Duncan MacGregord,e, Paul Waringf, William K. Murraye,g, Dale I. Godfreyb, Joseph A. Trapania,e, Ricky W. Johnstonea,e, and Mark J. Smytha,e,1 aCancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia; bDepartment of Microbiology and Immunology, University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia; cDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461; dDepartment of Anatomical Pathology, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia; eDepartment of Pathology, University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia; fPathology and Diagnostics, Genentech Incorporated, South San Francisco, CA 94080; and gDepartment of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia Edited by James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved December 19, 2008 (received for review September 10, 2008) In the present study, we have examined the effect of perforin (pfp) It remained unclear from these prior studies whether a loss of deficiency in 4 models of mouse B-cell lymphomagenesis. We have pfp was a direct cause of lymphoma or led indirectly to its examined pfp loss on the background of either Mlh1 tumor development as a result of loss of immune surveillance normally suppressor allele loss or oncogene expression [Ig heavy chain mediated by extrinsic cytolytic effector function. The avid ability (E␮)-v-Abl, E␮-myc, and vav-bcl2]. Pfp was shown to act as a of WT mice to reject B-cell lymphomas derived from pfp- suppressor of B-cell malignancies characteristically driven by v-Abl deficient mice in a pfp-dependent manner when transplanted or bcl-2, whereas Mlh loss cooperated in accelerating spontaneous supported the latter hypothesis.
    [Show full text]
  • Insights from Bel-2 and Mye: Malignancy Involves Abrogation of Apoptosis As Well As Sustained Proliferation 1 Suzanne Cory, 2'3 David L
    [CANCER RESEARCH(SUPPL.) 59, 1685s-1692s, April 1, 1999] Insights from Bel-2 and Mye: Malignancy Involves Abrogation of Apoptosis as well as Sustained Proliferation 1 Suzanne Cory, 2'3 David L. Vaux, Andreas Strasser, Alan W. Harris, and Jerry M. Adams The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Victoria 3050, Australia It is indeed an enormous honor and pleasure to introduce Drs. Suzanne Cory and Stanley Korsmeyer, this year's winners of the Mott Prize. I think no one would question the view that their seminal experiments radically changed the way we think about the process of cancer. If we look back about 10 or 15 years, programmed celt death was a very interesting phenomenon, but we had no idea what this meant in terms of cancer, although suggestions were made. It was certainly interesting in terms of development, but we had no idea about the mechanisms involved. Of course, all this has changed enormously over the last decade, and in terms of cancer particularly, through the seminal contributions of Suzanne Cory and Stan Korsmeyer and their colleagues. Now we know that not only do cancer cells have to escape proliferation controls, they also have to abolish cell death pathways. Not only is this incredibly important for our understanding of the mechanisms underlying cancer, but the way we think about therapy has been radically altered. And as was said already, it is very exciting and a great coincidence, perhaps, that the Sloan Prize this year is awarded to Bob Horvitz who has used very elegant genetics to dissect cell death pathways in C.
    [Show full text]
  • Course Catalog 2019-2020
    Blackburn College COLLEGE Course Catalog 2019-2020 700 College Ave Carlinville, IL 62626 www.blackburn.edu Admissions: 1-800-233-3550 2019-2020 Course Catalog Statement of Mission Blackburn College links a rigorous and affordable liberal arts education with a unique student-managed Work Program preparing graduates for careers, community engagement, and lifelong learning. COLLEGE The Blackburn Course Catalog is printed on paper containing post-consumer content. Cover design by a student worker as part of the Blackburn College Work Program. 2019-2020 Catalog Blackburn College is a private, four-year liberal arts college located in Carlinville, Illinois. A town of nearly 6,000 people, Carlinville is the county seat of Macoupin County. The beautiful 80 acre campus is 40 miles southwest of Springfield and 60 miles northeast of St. Louis, Missouri. Amtrak stops twice daily, linking the town with other Midwestern cities. Visitors are welcome at Blackburn and offices are open Monday through Friday from 8:00 a.m. to 5:00 p.m. Tour appointments can be made by calling (800) 233-3550, ext. 5517 during business hours; or by writing the Office of Admissions, Blackburn College, Carlinville, Illinois 62626; or by e-mail to [email protected]. Visit our web site at: www.blackburn.edu. 1 EDUCATIONAL OBJECTIVES The Faculty of Blackburn College expects each student to make progress toward achieving each of the following specific objectives of our concept of an effective modern liberal education: (Adopted by the faculty on January 20, 2005). 1. A Blackburn graduate should be able to think and communicate clearly and effectively.
    [Show full text]
  • 2017-2018 Catalog
    2017-2018 Catalog Blackburn College is a private, four-year liberal arts college located in Carlinville, Illinois. A town of nearly 6,000 people, Carlinville is the county seat of Macoupin County. The beautiful 80 acre campus is 40 miles southwest of Springfield and 60 miles northeast of St. Louis, Missouri. Amtrak stops twice daily, linking the town with other Midwestern cities. Visitors are welcome at Blackburn and offices are open Monday through Friday from 8:00 a.m. to 5:00 p.m. Tour appointments can be made by calling (800) 233-3550, ext. 5517 during business hours; or by writing the Office of Admissions, Blackburn College, Carlinville, Illinois 62626; or by e-mail to [email protected]. Visit our web site at: www.blackburn.edu. 1 EDUCATIONAL OBJECTIVES The Faculty of Blackburn College expects each student to make progress toward achieving each of the following specific objectives of our concept of an effective modern liberal education: (Adopted by the faculty on January 20, 2005). 1. A Blackburn graduate should be able to think and communicate clearly and effectively. 2. A Blackburn graduate should be able to demonstrate depth in a field of knowledge. 3. A Blackburn graduate should be able to think critically about the ways in which humanity gains and applies knowledge. Specifically, the graduate should have an informed understanding of a. the aesthetic and intellectual experience of literature and the arts; b. history and the concepts and analytic techniques of social science as modes of understanding current issues, problems, and the nature of human experience; and c.
    [Show full text]